Page History

Mapping of LOINC Part components used in susceptibility LOINC terms, specifically the ones that contain more than one antibiotics:

And the ones that contain strength:

This issue needs to be considered in association with CTP Project - Elaboration document on Susceptibility:
The modelling design (using the deposition observable / flattened format) is as follows:

‘‘Observable entity’ and
‘property type’ some ‘Susceptibility’ and
‘towards’ some <LOINC.component> and
‘technique’ some <LOINC.method> and
‘scale’ some <LOINC.scale>
‘time aspect’ some ‘Single point in time”
‘inheres in’ some ‘Microorganism’ and
'Direct site = 119303007 | Microbial isolate specimen (specimen) |'

In mapping ‘towards’ some <LOINC.component>:

1) We have mapped the LOINC parts containing one antibiotic to the equivalent substance

LP28719-0 1 Gatifloxacin (Mapped to: 116349004 Gatifloxacin (substance))
LP33354-9 1 Daptomycin (Mapped to: 406439009 Daptomycin (substance))

2) For the ones containing multiple substances, see the latest associated guideline for compound substances:

Combined substances added to the Substance hierarchy must meet the following criteria:

• The physiologic or biologic action of the combination must be enhanced or synergistic
• Combinations that do not have an enhanced or synergistic effect (e.g. combinations created for convenience) are out of scope.

Examples of combined substances that are in scope include:Ampicillin + sulbactamPiperacillin + tazobactam

Examples:

LP15937-3 1 Ampicillin+Sulbactam (Mapped to: 703744001 | Ampicillin and sulbactam (substance) |. A product concept also exist: 398786001 Product containing ampicillin and sulbactam (medicinal product))

LP29104-4 1 Quinupristin+Dalfopristin (No susbtance concept created yet. Product concept: 324352008 Product containing dalfopristin and quinupristin (medicinal product))

3) LOINC terms with an antibiotic component with strength specified:

LP229026-2 1 COMPONENT Moxifloxacin 0.5 ug/mL
LP229027-0 1 COMPONENT Moxifloxacin 1.0 ug/mL